The effect could be synergistically enhanced when combined with anti-programmed cell death protein 1 (PD-1) mAb mediated immune checkpoint inhibition, demonstrated in a therapeutic B16 melanoma experiment [208]. This evidence concerns the gene PDCD1 and melanoma.